What Repolar Pharmaceuticals does

Repolar Pharmaceuticals Oy is a Finnish private drug manufacturer founded in 2006 (with R&D dating to 2000) that develops, manufactures, and markets resin-based care products for humans and animals. The company is headquartered in Espoo, Finland with an operations office in Kolari (Finnish Lapland) near its raw material sourcing area, and operates with 1-10 employees. Repolar's products target wound care (acute and chronic wounds, pressure sores, diabetic wounds, leg ulcers, surgical wounds, burns), nail fungus, acne, and scalp/hair care in humans, and wound, ear, skin, and dental care in animals. Named brands include Abilar (wound salve), Abicin (nail lacquer), AbiCare (skincare), and the Ani series (AniVox, Abilar VET, AniWipe, AniDes, AniWash, AniLavo, AniPlax).

The company's core technology is its patented Resol Technology, a proprietary method for processing Norway spruce (Picea abies) resin collected by hand in northern Lapland into stable, water-soluble, non-sticky liquid solutions while preserving natural broad-spectrum antimicrobial properties. Cold-cleaned raw resin, supplemented by in vitro efficacy data against bacteria including MRSA and VRE and against dermatophytes, supports claims of effectiveness without antibiotics or cortisone. The company holds ISO 13485 certification for medical device design and manufacture, Finnish Key Flag (Avainlippu) designation, and has a body of peer-reviewed clinical and dermatology publications.

Commercially, Repolar sells through OTC pharmacy channels in Finland, veterinary clinics for animal products, and Finnish hospitals/health centres for professional wound care, with export distribution via Apotek1 in Norway. Revenue is generated through one-time product sales (no subscription or licensing disclosed) at undisclosed price points. The company is family-owned (Sipponen family and colleagues), has no disclosed external funding, and operates with an export sales director, R&D/quality manager, marketing team, and production technician, signaling a small but functional commercial infrastructure oriented toward incremental Nordic expansion.

Name

Repolar Pharmaceuticals

Legal name

Repolar Pharmaceuticals Oy

Website

https://repolar.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Short description

Repolar Pharmaceuticals Oy is a Finnish private drug manufacturer (founded 2006) that develops and sells resin-based wound care, nail fungus, skincare, and animal care products built on its patented Resol Technology, distributed through pharmacies, veterinary clinics, and hospitals in Finland and Norway.

Ownership category

akta.pro rank

Product category

Topical Wound and Skin Care Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industry

Wound Care, Bandaging & Consumables (Dressings, Sutures, Staplers) (HLAMAFAF)

Keywords

• Resin-based wound care
• Topical antimicrobial products
• Natural pharmaceuticals
• Veterinary skin care
• Medical device salve

Headquarters

HQ city

Espoo

HQ country

Finland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical/Medical Device Product Sales: One-time purchase model for medical products including wound care (Abilar), nail fungus treatment (Abicin), and acne care (AbiCare) for humans, plus animal care products (Ani series). Products sold through pharmacy and veterinary clinic distribution channels.
2. Animal Care Product Sales: Resin-based veterinary products including wound sprays, ear washes, shampoos, and dental care sold through animal clinics and pharmacies.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Repolar Pharmaceuticals researches, develops, manufactures and markets resin-based care products for humans and animals derived from Norway spruce (Picea abies) resin. Its product portfolio spans wound care salves (Abilar), nail fungus lacquer (Abicin), acne and scalp care (AbiCare), and a full veterinary line (Ani series — ear wash, wound spray, shampoo, wipes, dental care, rinsing liquid). Products are sold over-the-counter through pharmacies and veterinary clinics in Finland and selected Nordic markets.

Differentiator

Problem solved

Functional benefit

Brands

• Abilar: Resin-based wound care product line for humans and animals
• Abicin
• AbiCare
• AniVox
• AniWipe
• AniDes
• AniWash
• AniLavo
• AniPlax
• Resol

Products and services

• Abilar® 10% Resin Salve (Wound Balm) 10% Norway spruce resin salve for treatment of acute and chronic wounds, pressure sores, diabetic wounds, leg ulcers, complicated surgical wounds, and burn wounds. For human use; sold over-the-counter in pharmacies.
• Abicin® 30% Resin Lacquer 30% Norway spruce resin lacquer for the treatment of nail fungus infections and paronychia. Sold over-the-counter in pharmacies.
• AbiCare® Acne Cream

Quantifiable outcome

• Clinical studies show effective treatment of pressure ulcers, diabetic wounds, and complicated surgical wounds
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Luonnonperintösäätiö (Nature Heritage Foundation)minorOthersPartnership for forest conservation in North Ostrobothnia, Finland. For each Abilar resin salve sold, 1 square meter of Finnish forest is protected. Campaign to preserve old-growth forests and biodiversity in northern Finland.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Aromtech: Finnish ingredient and finished-products company specializing in natural, plant-derived health and skin care formulations. Thematically comparable as a fellow Finnish/Nordic natural-ingredient pharma and personal-care player, though with a different active-ingredient focus than Repolar's spruce resin.

Broad incumbents

• Galderma: Global dermatology pharmaceutical company (Differin, Epiduo, Benzac) with strong acne and skin-condition franchises. Comparable to Repolar's AbiCare acne/scalp line and indicative of the larger dermatology landscape Repolar's branded products compete within.
• Smith & Nephew: Global medical devices company with a sizable Advanced Wound Management portfolio (Acticoat, Allevyn, PICO). A broad incumbent whose wound-care franchise overlaps with Repolar's professional-use claims and competes for hospital formulary slots.
• Bayer Consumer Health: OTC healthcare giant behind Canesten (nail fungus) and Bepanthen (wound/skin care), directly competitive with Repolar's Abicin and Abilar lines in European pharmacies. A broad incumbent where overlap is partial but highly relevant to Repolar's core categories.

Direct peers

• Coloplast: Danish medical device company with a major wound and skin care franchise (Biatain, Comfeel) sold through pharmacies and hospitals. Highly comparable in business model and OTC wound/skin category overlap with Repolar's Abilar line.
• Vetoquinol: French independent animal health company covering companion and livestock pharmaceuticals including dermatology and wound care. Comparable in vet-channel focus and product overlap with Repolar's Ani-series veterinary wound and ear care products.
• Mölnlycke Health Care: Swedish-headquartered global leader in advanced wound care (Mepilex, Mepitel, Avance) and surgical solutions. Direct comparability to Repolar's wound-care franchise (Abilar resin salve for pressure ulcers, diabetic wounds, surgical wounds) with much larger scale.
• Virbac: France-based global animal health company with a strong dermatology, ear care, and wound care portfolio for companion animals. Directly comparable business model and product categories to Repolar's AniVox, AniDes, AniWash lines.
• ConvaTec: UK-listed medtech company focused on advanced wound care, ostomy, continence and infusion care. Comparable to Repolar in its wound-care focus and OTC/professional channel strategy across European markets.
• Dechra Pharmaceuticals: UK-listed veterinary pharmaceuticals specialist with deep coverage of companion and equine animal health, including dermatology and wound care. Closely comparable to Repolar's Ani-series in animal wound/skin/ear care and channel mix of vet clinics plus pharmacies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/repolar-ltd-

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Repolar Pharmaceuticals